abagovomab 0
abrilumab 0
afasevikumab 0
alacizumab_pegol 0
andecaliximab 0
ascrinvacumab 0
basiliximab 0
begelomab 0
bleselumab 0
brodalumab 0
camrelizumab 0
carotuximab 0
dezamizumab 0
diridavumab 0
domagrozumab 0
drozitumab 0
durvalumab 0
dusigitumab 0
efungumab 0
elgemtumab 0
enoblituzumab 0
eptinezumab 0
farletuzumab 0
fibatuzumab 0
flanvotumab 0
gantenerumab 0
ibritumomab 0
icrucumab 0
ifabotuzumab 0
ipilimumab 0
iratumumab 0
itolizumab 0
landogrozumab 0
lorvotuzumab_mertansin 0
lupartumab 0
necitumumab 0
nesvacumab 0
obiltoxaximab 0
orticumab 0
radretumab 0
ranibizumab 0
rinucumab 0
rituximab 0
sarilumab 0
secukinumab 0
sifalimumab 0
stamulumab 0
tabalumab 0
tavolixizumab 0
tesidolumab 0
timolumab 0
tisotumab 0
tositumomab 0
vadastuximab 0
vadastuximab_talirin 0
vandortuzumab_vedotin 0
vedolizumab 0
veltuzumab 0
xentuzumab 0
